ESTRO 2023 - Abstract Book

S947

Digital Posters

ESTRO 2023

Conclusion This study demonstrates the implementation of a new planning technique - TFRT , proving its feasibility in the modern clinical workflow. We experimented only 10 patients to see the impact of TFRT,and it has shown benefit over non TFRT plans in terms of reducing acute toxicities and also it can be easily incorporated in daily clincal workflow in the department . May be Additional prospective assessments are needed to check the complication rates.

PO-1184 Hypofractionated re-irradiation for locoregionally recurrent head and neck cancer

C. Becherini 1 , C. Mattioli 1 , N. Bertini 1 , V. Salvestrini 2 , I. Bonaparte 1 , I. Desideri 1 , V. Di Cataldo 1 , M. Loi 1 , B. Bettazzi 1 , L. Caprara 1 , M. Mangoni 1 , L. Livi 1 , P. Bonomo 1 1 AOU Careggi - University of Florence, Radiotherapy Unit, Florence, Italy; 2 Istituto Fiorentino di Cura e Assistenza (IFCA), CyberKnife Center, Florence, Italy Purpose or Objective Loco-regional recurrence is the predominant pattern of failure in patients affected by locally-advanced head and neck cancer (HNC). In both squamous cell carcinoma (SCC) and non-squamous histotypes, there is sparse evidence on the role of photon-based re (RE) irradiation (RT) in this setting. In the context of hypofractionation, different regimens have been adopted in previous experiences. The aim of our single-centre study is to evaluate the clinical outcome of recurrent, unresectable, HNC patients treated with hypofractionated Re-RT. Materials and Methods We retrospectively reviewed data from 53 consecutive patients with recurrent HNC treated at our centre with 2 courses of RT. All patients were deemed eligible for ReRT for a recurrent, previously irradiated unresectable HNC, following a multidisciplinary discussion of each case. Local control and survival were calculated using the Kaplan-Meier method and log rank test with time measured from the date of last day of Re-RT to date of progression or death. Results First curatively-intended course of RT was delivered from 1997 to 2020 with or without chemotherapy. Forty patients (75%) had a diagnosis of SCC, while 11 (21%) had other histotypes than SCC; for 2 (4%) patients, histotype was not available. Re RT was performed from 2012 to 2022 adopting a hypofractionated schedule. Details of Re-RT are shown in table 1. After a median follow-up of 22 months (range 0-49), 24 out of 53 patients were alive. Fourteen patients died for HNC disease (26%), 2 for toxicities related to treatments (4%) while 13 for other causes (24%). The median age of the cohort was 60 years. The median local control (LC) and the 1-year LC rate were 9 months (95% CI 5,6-12,3 months) and 74.2%, respectively. The median overall survival (OS) after re-RT and the 1-year OS rate were 11 months (95% CI 6.0-15.9) and 88,8% (Figure 1), respectively. At univariate analysis, a borderline negative association between time to Re-RT ≤ 12 months and LC was shown (p 0.06). No statistically significant correlation was observed in respect with age ≤ or > 70 years (p 0.19) or gender (p 0.15). A significant dependence of outcome after Re-RT from the hypofractionated schedule could not be demonstrated from our data (p 0.06).